Organon & Co. (NYSE:OGN) finished Thursday with an addition of $0.45 to close at $23.61, an upside of 1.94 percent. An average of 3,413,820 shares of common stock have been traded in the last five days. There was a gain of $2.10 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 2,470,525 shares traded, while the 50-day average volume stands at 2,204,136.
OGN stock has increased by 16.48% in the last month. The company shares reached their 1-month lowest point of $20.06 on 07/17/23. With the stock rallying to its 52-week high on 01/18/23, shares of the company touched a low of $18.87 and a high of $32.43 in 52 weeks. It has reached a new high 10 times so far this year and lost -15.47% or -$4.32 in price. In spite of this, the price is down -27.20% from the 52-week high.
Valuation Metrics
Organon & Co. (OGN) has a trailing price-to-earnings (P/E) ratio of 8.08. The stock’s beta is 0.74. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.98, and the price-to-cash flow ratio at 25.82.
Financial Health
The quick ratio of Organon & Co. for the three months ended June 29 was 1.10, and the current ratio was 1.60, indicating that the company is able to meet its debt obligations. Organon & Co.’s EBITDA margin for the year ending June 29 is 31.28%, while its operating margin for the same period stands at 14.90%. Its gross profit as reported stood at $3.88 billion compared to revenue of $6.17 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Organon & Co.’s return on assets was 7.00%.
Earnings Surprise
For the three-month period that ended June 29, Organon & Co. had $8.72 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $242.0 million in the quarter, while revenues were grew 3.31%. The analyst consensus anticipated Organon & Co.’s latest quarter earnings to come in at $1.01 per share, but it turned out to be $1.31, a 29.70% surprise. For the quarter, EBITDA amounted to $446.0 million. Shareholders own equity worth $255.57 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Organon & Co. (OGN) price momentum. RSI 9-day as of the close on 10 August was 71.12%, suggesting the stock is Overbought, with historical volatility in this time frame at 48.95%.
As of today, OGN’s price is $22.77 +9.76% or $2.10 from its 5-day moving average. OGN is currently trading +14.00% higher than its 20-day SMA and +8.95% higher than its 100-day SMA. However, the stock’s current price level is +22.52% above the SMA50 and -0.30% below the SMA200.
The stochastic %K and %D were 82.39% and 76.35%, respectively, and the average true range (ATR) was 0.76. With the 14-day stochastic at 83.62% and the average true range at 0.70, the RSI (14) stands at 68.25%. The stock has reached 1.19 on the 9-day MACD Oscillator while the 14-day reading was at 1.33.
Analyst Ratings
Raymond James launched coverage on Organon & Co. (NYSE: OGN) in its analyst report released on March 16, 2023. The firm assigned the stock an Outperform rating. The consensus rating for Organon & Co. (OGN) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell OGN, while 4 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 3 others rate it as a “buy”.
What is OGN’s price target for the next 12 months?
Analysts predict a range of price targets between $23.00 and $43.00, with a median target of $27.00. Taking a look at these predictions, the average price target given by analysts for Organon & Co. (OGN) stock is $30.00.
